5-[3-[3-methoxy-4-[[2-[(E)-2-phenylethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propyl]-3-[[2-[(E)-2-phenylethenyl]-1,3-oxazol-4-yl]methyl]-1,3-oxazolidine-2,4-dione

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-[3-[3-methoxy-4-[[2-[(E)-2-phenylethenyl]-1,3-oxazol-4-yl]methoxy]phenyl]propyl]-3-[[2-[(E)-2-phenylethenyl]-1,3-oxazol-4-yl]methyl]-1,3-oxazolidine-2,4-dione
• 化学式: C₃₇H₃₃N₃O₇
• 分子量: 631.7
• InChiKey: ZDDMGIYAHPNXRG-VQZJLROISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  47
• 可旋转键数：
  14
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  117
• 氢给体数：
  0
• 氢受体数：
  9

文献信息

• Tissue reactive compounds and compositions and uses thereof
  申请人：Angiotech International AG

  公开号：US20040219214A1

  公开（公告）日：2004-11-04

  A composition comprising a synthetic polymer, optionally in the presence of a drug, where the polymer comprises multiple activated groups. The multiple activated groups are reactive with functionality present on animal tissue, so that upon administration of the polymer to the tissue, the polymer binds to the tissue. Alternatively, the multiple activated groups are reactive with functionality present on a non-living surface, where the polymer binds to this surface to, e.g., increase the lubricity of the surface. When drug is present in the composition, the drug is then delivered to the site of polymer attachment.

  一种组合物包括一种合成聚合物，可选地存在药物，并且该聚合物包括多个活性基团。这些多个活性基团与动物组织上存在的功能性反应，因此在将聚合物注射到组织中时，聚合物与组织结合。或者，这些多个活性基团与非生物表面上存在的功能性反应，聚合物将与该表面结合，例如增加表面的润滑性。当组合物中存在药物时，药物将被传递到聚合物附着的部位。
• Soft tissue implants and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050142162A1

  公开（公告）日：2005-06-30

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

  软组织植入物（例如乳房、胸肌、下巴、面部、唇部和鼻部植入物）与抗瘢痕剂结合使用，以抑制动物体内植入物放置时可能发生的瘢痕形成。
• Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist
  申请人：Pharmacia Corporation

  公开号：US20040127470A1

  公开（公告）日：2004-07-01

  The present invention relates to a novel method of preventing and/or treating neoplasia disorders in a subject that is in need of such prevention or treatment by administering to the subject at least one Cox-2 inhibitor in combination with an EGF receptor antagonist. Compositions, pharmaceutical compositions and kits are also described.

  本发明涉及一种新型的预防和/或治疗肿瘤疾病的方法，通过向需要此类预防或治疗的受试者施用至少一种Cox-2抑制剂与EGF受体拮抗剂的组合物来实现。同时还描述了组合物、制药组合物和试剂盒。
• Drug delivery from rapid gelling polymer composition
  申请人：ANGIOTECH INTERNATIONAL AG

  公开号：EP2181704A2

  公开（公告）日：2010-05-05

  Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in prevention of surgical adhesions.

  本发明公开了一些组合物，这些组合物由两部分聚合物组成，在混合在一起时可迅速形成共价连接，从而实现药物输送。当需要快速粘附组织和形成凝胶并同时给药时，这种组合物特别适合用于各种与组织相关的应用。例如，这种组合物可用作组织密封剂、促进止血、实现组织粘合、提供组织增量以及防止手术粘连。
• Implantable sensors and implantable pumps and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050152946A1

  公开（公告）日：2005-07-14

  Pumps and sensors for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the pumps and sensors are implanted within an animal.

  用于与组织接触的泵和传感器与抗疤痕剂（如细胞周期抑制剂）结合使用，以抑制在动物体内植入泵和传感器时可能出现的疤痕。